

13 December 2024

Oncology Supplemental - Biological treatments

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Atezolizumab (Tecentriq)** <5
- **Durvalumab (Imfinzi)** <5
- **Nivolumab (Opdivo)** <5
- **Pembrolizumab (Keytruda)** 10
- **Chemotherapy**
 - Cisplatin+Vinorelbine 9
 - Gemcitabine+Carboplatin <5
 - Pembrolizumab+Paclitaxel+Carboplatin <5
 - Pembrolizumab+Pemetrexed+Carboplatin 8
 - Pemetrexed+Carboplatin <5
- **Radiotherapy** 145 lung patients treated
- **Chemotherapy AND Radiotherapy** 8
- **Osimertinib** <5

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- **CAPOX (Capecitabine with Oxaliplatin)** <5
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)** <5
- **Lonsurf (Trifluridine - tipiracil)** <5
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** <5
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** <5
- **Any other systemic anti-cancer therapy**
 - Carboplatin <5
 - Docetaxel <5
 - Etoposide+Carboplatin AUC5 <5
 - Flot 24
 - IMDG <5
 - OX 13
 - Paclitaxel Weekly <5
- **Palliative care only** Not available on RISOH
- **Zolbetuximab (Vyloy)** <5

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost

13 December 2024

and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.